Curaleaf Laboratories has introduced the launch of the UK’s first CE-certified liquid medical hashish inhaler, aiming to handle rising affected person and medical demand for a discreet and dependable inhalation methodology.
The Curaleaf Que Medical Inhalation System (QMID), designed in partnership with Jupiter Analysis LLC, can be accessible on prescription to all UK medical hashish clinics.
Its new rechargeable gadget makes use of Curaleaf’s already accessible EU-GMP liquid extract cartridges, and has a minimal lifespan of six months from first use, delivering as much as 240 inhalations with a 1.0mL cartridge.
QMID has been purpose-built from the bottom up as a medical gadget, and represents the primary CE-certified gadget of its form to hit the UK market.
Which means the inhaler has handed rigorous European regulatory scrutiny relating to security, reliability and repeatability throughout a number of use circumstances, and is formally deemed a Class IIa gadget beneath the EU Medical System Regulation.
Apart from giving each prescribers and sufferers confidence in its therapeutic suitability and regulatory compliance, this give attention to medical utility signifies that the amount of treatment delivered has been measured utilizing internationally recognised standards, making certain dependable supply throughout all administrations.
Activated upon inhalation, the dearth of buttons or menus means the gadget is straightforward to make use of, discreet and well-suited for each medical supervision and residential use for eligible sufferers who’re acceptable for inhaled hashish medicines.
Jonathan Hodgson, UK Managing Director at Curaleaf Worldwide, commented: “For the primary time, inhaled liquid hashish will be administered with managed precision by a registered handheld gadget — giving prescribers and sufferers new confidence in therapy supply.
“In contrast to unregulated or consumer-grade vaporisers, this gadget is purpose-built for medical use, with standardised supply, medical-grade elements, and compatibility with formulations that meet European Pharmacopoeia requirements.”
READ MORE: Curaleaf Worldwide’s Strategic Strikes in Europe: Unique Insights from Juan Martinez
The inhaler provides to Curaleaf’s present product vary within the UK, which incorporates oils, dried flower, capsules, pastilles, topicals and vaporisation merchandise. The corporate can be working with regulators in Germany, Poland, Australia and different markets to safe approvals for the brand new gadget.
Curaleaf Worldwide continues to collaborate with regulators, healthcare suppliers and pharmacists throughout a number of areas, aiming to develop entry to cannabinoid-based medicines in keeping with evolving medical frameworks.
Juan Martinez, Worldwide CEO at Curaleaf, stated: “The launch of this licensed Curaleaf gadget displays the subsequent section of innovation and positions Curaleaf on the forefront of a differentiated, pharma-grade supply platform that addresses rising world demand for precision hashish therapies.
“It’s a part of our wider mission to make medical hashish extra accessible, extra constant, and built-in into mainstream healthcare programs.”
